Toxicity of non-nucleoside analogue reverse transcriptase inhibitors

Pharmacology, Toxicology and Pharmaceutical Science

• Nonnucleoside Reverse Transcriptase Inhibitor 100%
• Virus Hepatitis 100%
• RNA Directed DNA Polymerase Inhibitor 100%
• Nucleoside Analog 100%
• Human Immunodeficiency Virus Infection 66%
• Nevirapine 66%
• Efavirenz 66%
• Mixed Infection 66%
• Hepatotoxicity 66%
• Delavirdine 66%
• HIV 33%
• Lipodystrophy 33%
• Syndrome 33%
• Hepatitis B Virus 33%
• Liver Disease 33%
• Drug Toxicity 33%
• Aminotransferase 33%
• Allergic Reaction 33%
• Opportunistic Infection 33%
• Hepatitis C Virus 33%
• Liver Enzyme 33%
• Mitochondrial Toxicity 33%
• Etiology 33%

Keyphrases

• Highly Active Antiretroviral Therapy (HAART) 100%
• Nucleoside Reverse Transcriptase Inhibitors 100%
• Non-nucleoside 100%
• Viral Hepatitis 75%
• Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) 75%
• HIV Infection 50%
• Nevirapine 50%
• Efavirenz 50%
• Co-infection 50%
• Hepatitis C Virus 25%
• Steatohepatitis 25%
• Close Monitoring 25%
• Hepatitis B Virus 25%
• Drug Toxicity 25%
• Substance Abuse 25%
• Opportunistic Infections 25%
• Hepatotoxicity 25%
• Liver Enzymes 25%
• Hepatotoxic 25%
• Mitochondrial Toxicity 25%
• Antiretroviral Therapy Regimens 25%
• Transaminases 25%
• Multiple Etiologies 25%
• Pre-existing Liver Disease 25%
• Virological Resistance 25%
• Toxicity Risk 25%
• Lipodystrophy Syndrome 25%
• Patients with HIV 25%